UBS/CALL/IDORSIA/2.505/0.2/20.12.24 Stock

Warrant

UKBSNU

CH1351208975

Market Closed - Swiss Exchange 11:20:01 2024-06-13 am EDT
0.17 ^CHF	-5.56%

Current month

-32.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/2.505/0.2/20.12.24

Latest news about IDORSIA LTD

Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds	Jun. 28	GL
Swiss Cantonal Court Approves Amendments to Idorsia's Convertible Bonds	Jun. 26	MT
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds	Jun. 25	GL
Carmat: changes in corporate governance	Jun. 25	CF

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	UKBSNU
ISIN	CH1351208975
Date issued	2024-05-21
Strike	2.505 CHF
Maturity	2024-12-20 (174 Days)
Parity	5 : 1
Emission price	0.2 CHF
Emission volume	N/A
Settlement	physical
Currency	CHF

Technical Indicators

Highest since issue	0.26 CHF
Lowest since issue	0.17 CHF
Spread	0.02 CHF
Spread %	11.76%

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company